Clinical Trial Update: NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) [Phase 2]

View source ↗

Summary

NS Pharma's NS-089/NCNP-02-201 is a Phase 2 trial for Duchenne muscular dystrophy in boys with exon 44 mutations, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• NS-089/NCNP-02-201

Snippet

Sponsor: NS Pharma, Inc. | Conditions: Duchenne Muscular Dystrophy, Exon 44 | Phase 2 | Status: RECRUITING